Eli Lilly and Co (LLY)
756.05
-20.70
(-2.66%)
USD |
NYSE |
May 02, 16:00
744.00
-12.05
(-1.59%)
After-Hours: 17:29
Eli Lilly Cash from Financing (TTM): 2.772B for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 2.772B |
December 31, 2023 | 3.496B |
September 30, 2023 | -1.190B |
June 30, 2023 | -3.026B |
March 31, 2023 | -2.116B |
December 31, 2022 | -5.407B |
September 30, 2022 | -5.792B |
June 30, 2022 | -4.992B |
March 31, 2022 | -5.951B |
December 31, 2021 | -4.131B |
September 30, 2021 | -3.896B |
June 30, 2021 | -3.712B |
March 31, 2021 | -4.302B |
December 31, 2020 | -3.137B |
September 30, 2020 | -2.959B |
June 30, 2020 | -4.373B |
March 31, 2020 | -3.586B |
December 31, 2019 | -2.324B |
September 30, 2019 | -2.851B |
June 30, 2019 | -725.00M |
March 31, 2019 | -670.60M |
December 31, 2018 | -5.905B |
September 30, 2018 | -4.808B |
June 30, 2018 | -4.740B |
March 31, 2018 | -2.848B |
Date | Value |
---|---|
December 31, 2017 | 142.60M |
September 30, 2017 | 1.070B |
June 30, 2017 | -30.70M |
March 31, 2017 | -511.30M |
December 31, 2016 | -559.80M |
September 30, 2016 | -1.816B |
June 30, 2016 | -1.812B |
March 31, 2016 | -3.334B |
December 31, 2015 | -3.111B |
September 30, 2015 | -702.50M |
June 30, 2015 | -513.20M |
March 31, 2015 | -272.50M |
December 31, 2014 | -166.40M |
September 30, 2014 | -2.740B |
June 30, 2014 | -2.863B |
March 31, 2014 | -2.694B |
December 31, 2013 | -3.829B |
September 30, 2013 | -4.058B |
June 30, 2013 | -4.074B |
March 31, 2013 | -4.093B |
December 31, 2012 | -4.420B |
September 30, 2012 | -3.805B |
June 30, 2012 | -3.702B |
March 31, 2012 | -3.713B |
December 31, 2011 | -2.370B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-5.951B
Minimum
Mar 2022
3.496B
Maximum
Dec 2023
-2.910B
Average
-3.361B
Median
Cash from Financing (TTM) Benchmarks
Amgen Inc | 21.05B |
Madrigal Pharmaceuticals Inc | 595.12M |
Vertex Pharmaceuticals Inc | -562.20M |
Viking Therapeutics Inc | 873.23M |
Moderna Inc | -1.377B |